RNAi knockdown of pik3ca preferentially inhibits invasion of mutant PIK3CA cells

World Journal of Gastroenterology

Volumn 17, Issue 32, 2011, Pages 3700-3708

  Zhou, Xin Ke ^a,b   Tang, Sheng Song ^a   Yi, Gao ^b   Hou, Min ^b   Chen, Jin Hui ^a,c   Yang, Bo ^b   Liu, Ji Fang ^b   He, Zhi Min ^b  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c SOUTH CHINA SEA INSTITUTE OF OCEANOLOGY   (China)

Author keywords

Gastric cancer; Metastasis; PI3K Akt pathway; PIK3CA; RNAi

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE P110 ALPHA; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EXON; GENE MUTATION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; RNA SYNTHESIS; STOMACH CANCER; WOUND HEALING;

EID: 80053908871     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i32.3700     Document Type: Article

References (28)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across fve continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150
2. Milosavljevic T, Kostic-Milosavljevic M, Jovanovic I, Krstic M. Gastrointestinal and liver tumours and public health in Europe. Eur Rev Med Pharmacol Sci 2010; 14: 259-262
3. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811
4. Zamore PD. RNA interference: listening to the sound of silence. Nat Struct Biol 2001; 8: 746-750
5. Wilda M, Fuchs U, Wössmann W, Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 2002; 21: 5716-5724
6. Volinia S, Hiles I, Ormondroyd E, Nizetic D, Antonacci R, Rocchi M, Waterfield MD. Molecular cloning, cDNA sequence, and chromosomal localization of the human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene. Genomics 1994; 24: 472-477
7. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004; 3: 772-775
8. Li VS, Wong CW, Chan TL, Chan AS, Zhao W, Chu KM, So S, Chen X, Yuen ST, Leung SY. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 2005; 5: 29
9. Lin Y, Jiang X, Shen Y, Li M, Ma H, Xing M, Lu Y. Frequent mutations and amplifcations of the PIK3CA gene in pituitary tumors. Endocr Relat Cancer 2009; 16: 301-310
10. Liu JF, Zhou XK, Chen JH, Yi G, Chen HG, Ba MC, Lin SQ, Qi YC. Up-regulation of PIK3CA promotes metastasis in gastric carcinoma. World J Gastroenterol 2010; 16: 4986-4991
11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods 2001; 25: 402-408
12. Liu JF, Li W, Qi YC. Effects of PIK3CA overexpression on invasion of gastric cancer cells. Chin J Cancer Prev Treat 2010; 17: 1727-1729
13. Endoh Y, Sakata K, Tamura G, Ohmura K, Ajioka Y, Wata-nabe H, Motoyama T. Cellular phenotypes of differentiated-type adenocarcinomas and precancerous lesions of the stomach are dependent on the genetic pathways. J Pathol 2000; 191: 257-263
14. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501
15. Takeda A, Osaki M, Adachi K, Honjo S, Ito H. Role of the phosphatidylinositol 3'-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. Pancreas 2004; 28: 353-358
16. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN, Larue L. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squa-mous cell carcinoma lines. Cancer Res 2003; 63: 2172-2178
17. Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT, Smyrk TC. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Car-cinogenesis 2002; 23: 201-205
18. Altomare DA, Tanno S, De Rienzo A, Klein-Szanto AJ, Tan-no S, Skele KL, Hoffman JP, Testa JR. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem 2002; 87: 470-476
19. Semba S, Moriya T, Kimura W, Yamakawa M. Phosphory-lated Akt/PKB controls cell growth and apoptosis in in-traductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas. Pancreas 2003; 26: 250-257
20. Cicenas J. The potential role of Akt phosphorylation in human cancers. Int J Biol Markers 2008; 23: 1-9
21. Vasko V, Saji M, Hardy E, Kruhlak M, Larin A, Savchenko V, Miyakawa M, Isozaki O, Murakami H, Tsushima T, Burman KD, De Micco C, Ringel MD. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 2004; 41: 161-170
22. Cerutti H. RNA interference: traveling in the cell and gaining functions? Trends Genet 2003; 19: 39-46
23. Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003; 4: 457-467
24. Singh B, Reddy PG, Goberdhan A, Walsh C, Dao S, Ngai I, Chou TC, O-Charoenrat P, Levine AJ, Rao PH, Stoffel A. P53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev 2002; 16: 984-993
25. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21: 99-102
26. Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD, Yan H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004; 64: 5048-5050
27. Nguyen T, Menocal EM, Harborth J, Fruehauf JH. RNAi therapeutics: an update on delivery. Curr Opin Mol Ther 2008; 10: 158-167
28. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009; 8: 129-138